HomeAI · summaries
Storia in 9 fonti
Samsung Biologics, opa da 1,8 miliardi sulla svizzera PolyPeptide: focus sui farmaci dimagranti | MilanoFinanza News
La controllata del gruppo Samsung lancia un'opa da 1,46 miliardi di franchi svizzeri (1,8 miliardi di dollari) su PolyPeptide per rafforzarsi nei farmaci peptidici, trainati dalla domanda di terapie anti-obesità
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
swissinfo.ch
Samsung Biologics to Buy PolyPeptide in $1.8 Billion Deal
(Bloomberg) -- Samsung Biologics Co. agreed to acquire Switzerland’s PolyPeptide Group AG in an all-cash deal that values the contract drugmaker’s equity at about 1.46 billion…
- ·
cnbc.com
Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal
South Korea's Samsung Biologics said on Monday that it had made an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) for Switzerland's PolyPeptide Group.
